

Date: 26/06/2019

Private and Confidential

Ms Alison Hewitt HM Senior Coroner City of London Divisional Clinical Director Barts Heart Centre St Bartholomew's Hospital West Smithfield London EC1A 7BE

Switchboard: 020 3416 5000

Email:

www.bartshealth.nhs.uk

Dear Ms Hewitt

RE: Chand Ali (deceased), Regulation 28 Report to Prevent Future Deaths.

In response to this regulation 28 report our lead pharmacist for Barts Heart Centre, has undertaken an extensive review of the evidence available to support the caution highlighted in the British National Formulary for use of Cyclizine in patients with severe heart failure along with consideration of alternative anti-emetics that are available for our use.

I have enclosed report but in summary, he has identified that the evidence base for this caution is very limited and its validity to clinical practice remains questionable. He has considered the 3 alternative anti-emetic drugs commonly used in our hospital but each of these come with their own cardiac cautions and do not offer a suitable alternative to the use of cyclizine.

As instructed, we will warn all our teams of the risks of cyclizine in heart failure patients. However, it is inevitable that cyclizine will still be used in some patients with heart failure as it may be assessed as the best option in many situations.

Yours Sincerely

Cardiology Consultant
Divisional Director, Barts Heart Centre

CC: Medical Director St Bartholomew's Hospital Chief Medical Officer, Barts Health NHS Trust

